A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome
Trial details
- Registry ID
- NCT05898620
- Drugs studied
- NGN-401
TrialRedline tracks 1 clinical trial sponsored by Neurogene Inc.: 1 Phase 3.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett SyndromeNCT05898620 | NGN-401 | Active not recruiting | 2029-12Estimated |
Names as written in the registry records.
NCT05898620 · Neurogene Inc.
Before: Recruiting. After: Active not recruiting.